Table 6.

Adjusted HRs for EBV status on survival outcomes

Overall mortalityLymphoma-specific mortality
All DLBCLsHR (95% CI)PHR (95% CI)P
 Multivariable model 1: adjusting for IPI3.3 (1.6–6.6)<0.014.6 (1.8–11.4)<0.01
 Multivariable model 2: adjusting for propensity scorea2.1 (1.0–4.5)0.062.8 (1.1–7.7)0.04
Centroblastic DLBCL
 Multivariable model 1: adjusting for IPI1.9 (0.9–3.8)0.082.8 (1.2–6.8)0.02
 Multivariable model 2: adjusting for propensity scorea2.9 (1.1–7.4)0.034.3 (1.1–16.8)0.04
Patients on standard chemotherapy
 Multivariable model 1: adjusting for IPI3.3 (1.4–7.8)<0.013.3 (1.1–10.0)0.03
 Multivariable model 2: adjusting for propensity scorea2.9 (1.1–7.4)0.033.1 (0.9–10.0)0.06
  • aModel adjusted for propensity score. Variables used to create propensity score include: age (≤60 vs. >60 years), gender, ethnicity (Hispanic vs. non-Hispanic), DLBCL subtype (centroblastic, immunoblastic, plasmablastic), stage (III, IV, vs. others), extranodal involvement (disseminated vs. other), elevated serum LDH level at DLBCL diagnosis, ECOG performance status (≥2 vs. <2), prior AIDS diagnosis (yes vs. no), and CD4 cell count at diagnosis (<200 vs. ≥200/mm3).